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The liver peptide hepcidin regulates body iron, is up-
regulated in iron overload and inflammation, and is
downregulated in iron deficiency/hypoxia. The trans-
membrane serine protease matriptase-2 (TMPRSS6)
inhibits the hepcidin response and its mutational
inactivation causes iron-deficient anemia in mice
and humans. Here we confirm the inhibitory effect
of matriptase-2 on hepcidin promoter; we show
that matriptase-2 lacking the serine protease do-
main, identified in the anemic Mask mouse (matrip-
tase-2MASK), is fully inactive and that mutant R774C
found in patients with genetic iron deficiency has
decreased inhibitory activity. Matriptase-2 cleaves
hemojuvelin (HJV), a regulator of hepcidin, on plasma
membrane; matriptase-2MASK shows no cleavage
activity and the human mutant only partial cleavage
capacity. Matriptase-2 interacts with HJV through
the ectodomain since the interaction is conserved
in matriptase-2MASK. The expression of matriptase-
2 mutants in zebrafish results in anemia, confirming
the matriptase-2 role in ironmetabolism and its inter-
action with HJV.
INTRODUCTION
The liver peptide hepcidin is themaster regulator of intestinal and
macrophage iron release to circulating transferrin and thus of the
body iron supply, through its ability to bind, internalize, and de-
grade the cellular iron exporter ferroportin (Nemeth et al.,
2004). Hepcidin expression increases in inflammation and iron
overload to limit iron availability. The inflammatory cytokines, es-
pecially IL-6, activate hepcidin through STAT3-mediated signal-
ing (Wrighting and Andrews, 2006; Verga Falzacappa et al.,
2007; Pietrangelo et al., 2007) to sequester iron in macrophages.
Low/inappropriate hepcidin production occurs in most types of
hemochromatosis (Camaschella, 2005), but especially in the se-
vere juvenile form due to hemojuvelin (HJV) mutations (Papani-
kolaou et al., 2004; Lanzara et al., 2004). Genes (HFE, TFR2,
HJV) have been identified that affect hepcidin regulation, al-502 Cell Metabolism 8, 502–511, December 3, 2008 ª2008 Elsevierthough the molecular mechanisms are not fully understood.
The main activator of hepcidin transcription is HJV, a glycosil-
phosphatidylinositol (GPI)-anchored protein that behaves as
coreceptor of bone morphogenetic proteins (BMPs) (Babitt
et al., 2006), which signal through son ofmothers against decap-
entaplegic (SMAD) proteins. SMAD4 liver conditional knockout
mice develop iron overload due to downregulation of hepcidin
(Wang et al., 2005), supporting the SMAD role in the pathway
and linking the reduction of BMP signaling to iron overload.
Soluble HJV (s-HJV) in vitro acts as a ‘‘decoy-receptor’’ com-
peting withmembraneHJV (m-HJV) for the BMP ligand (Lin et al.,
2005). Chronic injection of s-HJV causes hemochromatosis in
mice (Babitt et al., 2007), indicating that s-HJV can inhibit hepci-
din and increase iron absorption in vivo. HJV is cleaved by furin
at position 335 (Valore and Ganz, 2008; Silvestri et al., 2008), re-
leasing s-HJV as a major (42 kDa) and a minor (33 kDa) compo-
nent into the cell-culture supernatant. We have shown that furin
cleavage in vitro occurs in conditions of iron deficiency and
chemically induced hypoxia (Silvestri et al., 2008).
Recently a genetic inability to downregulate hepcidin has been
recognized, due to TMPRSS6mutations (Du et al., 2008; Finberg
et al., 2008). TMPRSS6 encodes a type II plasmamembrane ser-
ine protease, also known as matriptase-2, which belongs to
a family of cell-surface proteolytic enzymes (type II transmem-
brane serine protease, TTSP) (Velasco et al., 2002), highly con-
served in mammals (Ramsay et al., 2008). Matriptase-2 is mainly
expressed in liver both in humans and in mice. The protein has
a short cytoplasmic tail and a transmembrane domain. The
extracellular domain contains multiple motifs and domains in-
cluding two complement protein subcomponents C1r/C1motifs,
urchin embryonic growth factor and bone morphogenetic pro-
tein 1 (CUB) domains; three low density lipoprotein receptor
class A (LDLR) repeats; a prodomain region that contains the
cleavage site for protease activation; and a carboxy-terminal
catalytic domain (Velasco et al., 2002). Matriptase-2 has a strong
effect on hepcidin suppression as shown by the Mask mouse
model, which results from a deletion of the serine protease do-
main. Mask mice have abnormal hair distribution and iron-defi-
ciency anemia, due to decreased iron absorption because of in-
appropriately high hepcidin levels (Du et al., 2008). A similar
phenotype is present in the Tmprss6-deficient mice (Folgueras
et al., 2008). In transfected HepG2 cells matriptase-2 inhibits
hepcidin activation by multiple stimuli (BMP, HJV, SMAD1,Inc.
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matriptase-2 remains speculative and was proposed to occur
through a novel pathway, independent from known hepcidin reg-
ulatory pathways (Du et al., 2008).
The function of matriptase-2 is maintained in humans. Muta-
tions of matriptase-2 lead to iron-refractory iron-deficient ane-
mia (IRIDA). IRIDA patients have remarkably high hepcidin levels,
in spite of iron deficiency. Nonsense/frameshift/splice mutations
lead to truncated variants reminiscent of matriptase-2MASK. Mis-
sense changes in matriptase-2 have also been identified, which
affect conserved residues: G442R in the second CUB domain,
D521N in the second LDLR domain and R774C in the protease
domain (Finberg et al., 2008). Results in mice and humans indi-
cate that matriptase-2 is required to sense iron deficiency in
mammals (Du et al., 2008).
In this paper we studied wild-type and matriptase-2 mutants
for their ability to downregulate hepcidin expression. We provide
evidence that matriptase-2 inhibits hepcidin by cleaving HJV
from plasmamembrane. Mutants of matriptase, that are inactive
(matriptase-2MASK) or partially active (matriptase-2R774C) in
cleaving HJV, permit the continued expression of hepcidin.
RESULTS
Matriptase-2 Processing
To analyze the maturation and processing of wild-type and
mutant matriptase-2, we mutagenized pcDNA3.1-matriptase-
2-FLAG expressing vector (kindly provided by Prof. C. Lopez-
Otin) to obtain the human homolog of ‘‘Mask’’ lacking the cata-
lytic domain (Du et al., 2008) and a mutation (R774C) described
in an IRIDA patient, replacing arginine with an extra cysteine at
position 774 in the serine protease domain (Finberg et al.,
2008) (Figure 1A). Immunofluorescence of cells transfected
with plasmids expressing either wild-type or mutant matrip-
tase-2 revealed that the expressed proteins were localized in
structures resembling the endoplasmic reticulum in permeabi-
lized cells (Figure S1, P). In nonpermeabilized conditions the ex-
pressed proteins were present on the plasma membrane
(Figure S1, UP). When quantified by a binding assay the amount
of matriptase-2R774C was reduced on the cell surface, suggest-
ing that the amino acid substitution interfered with the correct lo-
calization of the protein. In contrast, the amount of surface ma-
triptase-2MASK was greater than that of the wild-type protein
(Figure 1B), likely due to its inability to undergo the autocleavage
of the serine protease domain.
To study the processing and maturation of matriptase-2 vari-
ants, electron microscopy and morphometric analysis were per-
formed on transfected HeLa cells. As shown in Figure 1C, 18 hr
after transfection matriptase-2wt andmatriptase-2MASK localized
mainly to the plasma membrane and in lesser amounts to the
Golgi (G) and the endoplasmic reticulum (ER). In contrast, ma-
triptase-2R774C predominantly accumulated in the ER and
showed lower expression in the plasma membrane.
Expression of matriptase-2wt results in the release into theme-
dium of two species, migrating at about 30 and 60 kDa. These
shorter forms originate from the cleavage of the ectodomain,
which releases the C terminus of the protein (Figure 1D). The
molecular weight of the bands, their reactivity to the anti-FLAG
antibody, and their insensitivity to peptide N-GlycosidaseCellF (PNGase) treatment (data not shown) suggest that they repre-
sent the serine protease domain, which lacks N-linked-carbohy-
drates (Ramsay et al., 2008) and migrates as a single (30 kDa) or
dimeric (60 kDa) species. The same fragments are undetectable
in the supernatant of cells transfected with matriptase-2MASK,
which lacks the proteolytic domain, supporting the interpreta-
tion. There are relatively fewer soluble fragments in medium
from cells expressing matriptase-2R774C, suggesting that an
active serine-protease domain and/or a correct protein folding
are essential to release the serine protease domain.
Matriptase-2 Inhibits HJV-Mediated Hepcidin Activation
To study the effect of matriptase-2 on hepcidin expression, we
transfected Hep3B cells with a hepcidin promoter/firefly lucifer-
ase reporter construct (Hep-Luc) and a renilla luciferase vector
(Pagani et al., 2008). The expression of matriptase-2wt or matrip-
tase-2 mutants did not alter hepcidin promoter activity in basal
conditions nor after BMP2 stimulation (Figure 2A). As expected,
the presence of HJV enhanced hepcidin activation. Coexpres-
sion of HJV and matriptase-2wt, however, significantly de-
creased hepcidin reporter gene activation. No decrease in hep-
cidin expression resulted when HJV was coexpressed with
matriptase-2MASK, while expression of matriptase-2R774C led to
a partial inhibition. A comparable trend was observed when
HJV-matriptase-2 cotransfected cells were treated with BMP2
(Figure 2A), suggesting that matriptase-2 specifically blocks
the HJV-mediated effect. To verify the minimal effective concen-
tration of matriptase-2, Hep3B cells were transfected with esca-
lating concentrations of the serine protease. Matriptase-2wt
inhibited hepcidin activation in a dose-dependent manner;
matriptase-2R774C was less active and reached an inhibitory
effect comparable to that of the wild-type protein only at high
concentrations, butmatriptase-2MASKwas inactive at all concen-
trations tested (Figure 2B).
Matriptase-2 Cleaves HJV
Based on the observation that matriptase-2 inhibits the HJV-
mediated hepcidin activation, we assessed whether it cleaved
HJV. Coexpression of matriptase-2wt and HJV caused a de-
crease of total (both full length and 33 kDa) HJV. No decrease
in HJV occurred upon coexpression of matriptase-2MASK, sug-
gesting that matriptase-2 cleaves HJV (Figure 3A). Since matrip-
tase-2 is a transmembrane protease, we hypothesized that it
cleaves cell-surface HJV (m-HJV). To test this hypothesis,
HeLa cells were transfected with HJV and increasing concentra-
tions of matriptase-2wt or the matriptase-mutants. Cell-surface
HJV decreased in a dose-dependent manner in cells expressing
matriptase-2wt (Figure 3B). In contrast, m-HJVwas unchanged in
cells transfected with matriptase-2MASK and partially decreased
in the presence of matriptase-2R774C, indicating that the integrity
of the protease domain is essential for an efficient cleavage of
m-HJV (Figure 3B).
To further assess the residual amount of m-HJV after matrip-
tase-2 cleavage, transfected cells were treated with a phospha-
tidylinositol-specific phospholipase (PI-PLC) that specifically
cuts GPI-anchored proteins, and the cleavage products in the
supernatant were analyzed. HJV released by PI-PLC migrates
as approximately 50 kDa and 33 kDa forms under partially reduc-
ing conditions (Figure 3A; lane 2, PI-PLC top panel) or mainly asMetabolism 8, 502–511, December 3, 2008 ª2008 Elsevier Inc. 503
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(A) Schematic representation of matriptase-2 (MT2) functional domains and localization of the studied mutations (modified from [Ramsay et al., 2008)]. TM: trans-
membrane domain; SEA: sea urchin sperm protein, enteropeptidase agrin; CUB: complement protein subcomponents C1r/C1s, urchin embryonic growth factor,
and bone morphogenetic protein 1 domain; L: low density lipoprotein receptor class A domain; S/P: serine protease domain. The arrow indicates the cleavage
activation site, and asterisks indicate the predicted consensus N-glycosylation sites.
(B) Quantification of membrane bound matriptase-2 (m-MT2) by binding assay. HeLa cells were transiently transfected with the wild-type and mutant expressing
vectors, or the empty vector, and analyzed for the amount of matriptase-2 on the cell surface. The amount was calculated as the ratio between the absorbance of
unpermeabilized and permeabilized cells. Error bars indicate SD. Statistical significance was calculated on a total of three experiments, made in triplicate. Exact
P values are shown above bars.
(C) Electron microscopy and morphometric analysis of MT2wt, MT2R774C, and MT2MASK. Error bars indicate SD.
(D) Characterization of MT2. Whole cell extracts and concentrated media of transiently transfected HeLa cells were analyzed by 10% SDS-PAGE. Western blot
was performed following standard procedures; MT2 was revealed by the anti-FLAG antibody.
s-MT2: soluble MT2; S/P: serine protease domain; CL: cellular lysates; CM: conditioned medium. The equal loading was verified by a-tubulin.33 kDa fragments under strong reducing conditions (Figure 3A;
lane 2, PI-PLC bottom panel).
When HJV was coexpressed with matriptase-2wt, because of
matriptase-2 proteolytic activity, only traces of residual m-HJV
were cleaved by PI-PLC (Figure 3A; lane 3, PI-PLC panels). As in-
dicated by the amount ofm-HJV released byPI-PLC,matriptase-
2MASK was fully inactive (Figure 3A; lane 5, PI-PLC panels),
whereas matriptase-2R774C (Figure 3A; lane 4, PI-PLC panels)
had partial activity.
Examination of the cleavage products in the culture media re-
leased by matriptase-2 revealed bands migrating between 25
and 30 kDa, in addition to decreased 42 and 33 kDa s-HJV spe-
cies (Figure 3A; lane 3, CM panel). In contrast, the former frag-
ments were not present in the media from cells transfected
with matriptase-2MASK (Figure 3A; lane 5, CM panel) and only504 Cell Metabolism 8, 502–511, December 3, 2008 ª2008 Elsevierbarely present in the media from cells expressing matriptase-
2R774C (Figure 3A; lane 4, CM panel).
To clarify the origin of the cleavage products, we took advan-
tage of two previously developed HJV variants. W191C, which is
incorrectly processed, retained into ER and is unable to reach
the cell surface. This mutant form is released into the medium
as a 42 kDa s-HJV (Silvestri et al., 2007). A second HJV mutant
R335Q is efficiently exported to plasma membrane but does
not release s-HJV, since the amino acid change affects the furin
consensus cleavage site (Silvestri et al., 2008). PI-PLC cleaves
m-HJV only in cells transfected with HJVwt (Figure 3C; lane 2)
and HJVR335Q (Figure 3C; lane 4) but not with HJVW191C
(Figure 3C; lane 3). When matriptase-2 was coexpressed with
HJVwt or HJVR335Q, PI-PLC did not releasem-HJV due to the ser-
ine protease activity (Figure 3C; lanes 5 and 7, PI-PLC panel).Inc.
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(Figure 3C; lane 7, CM panel) release in the supernatant the
same cleavage products as from cleavage of HJVwt (Figure 3C;
lane 5, CM panel). In contrast, when matriptase-2wt was coex-
pressed with HJVW191C (Figure 3C; lane 6, CM panel), the 42
kDa s-HJV form was decreased, but no additional fragments
were observed. In the same experiments matriptase-2MASK
was used as an inactive control (Figure 3C; lanes 8–10). We
conclude that the 25–30 kDa fragments produced by the matrip-
tase-2 cleavage originate from m-HJV and hypothesize that the
42 kDa s-HJV decrease follows the reduction of HJV due to ma-
triptase-2 overexpression.
Figure 2. Matriptase-2 Modulation of the
Hepcidin Promoter Responses
(A) Hepcidin promoter responses by BMP2 and
HJV, in the presence of matriptase-2 (MT2). A fire-
fly luciferase reporter driven by 2.9 kb of the prox-
imal hepcidin promoter was cotransfected into
Hep3B cells with pRL-TK, either alone or with
HJV and/or MT2 expressing vectors. Relative lu-
ciferase activity is calculated as reported in mate-
rial and method and expressed as amultiple of the
activity of cells transfected with the reporter alone.
Experiments, made in triplicate, were performed
three times. Error bars indicate SD. Exact P values
are shown above bars.
(B) Dose-dependent modulation of the hepcidin
activity by MT2. Hep3B cells were transfected
with increasing concentrations of wild-type or mu-
tant MT2 expressing vectors in the presence of
fixed amount of HJV expressing vector and
treated or not with BMP2 (50 ng/ml). The fold in-
duction is calculated as a ratio between the
MT2-mediated and the mock-mediated hepcidin
promoter activity, calculated as described in (A).
Experiments, made in triplicate, were performed
three times. Error bars indicate SD. Exact P values
are shown above bars.
To demonstrate the specificity of the
process, we tested matriptase-2wt cleav-
age ability on uromodulin, a GPI-an-
chored protein mainly expressed in the
kidney (Bernascone et al., 2006). As
shown in Figure S2, total, membrane-as-
sociated, and soluble uromodulin were
not affected by the serine protease.
Matriptase-2 Does Not
Cleave s-HJV
To understand whether the 42 kDa s-HJV
is cleaved directly bymatriptase-2, we in-
cubated matriptase-2-transfected cells
with exogenous s-HJV (Figure 4A) and
observed that matriptase-2-overex-
pressing cells did not cleave s-HJV inme-
dia of HJV-transfected cells. To confirm
that the decrease of HJV in cell extracts
was due to matriptase-2 overexpression,
cells were transfectedwith increasing amounts ofmatriptase-2wt
and constant amounts of HJV (Figure 4B). At low expression
levels, matriptase-2wt reduced only m-HJV, releasing the corre-
sponding soluble fragments in the supernatant. We also ob-
served that the serine-protease domain cleaved from matrip-
tase-2 ectodomain was released in the cell-culture
supernatant. To understand whether the soluble matriptase-2
domain retained proteolytic activity on HJV, we incubated
HJV-transfected cells with conditioned media from matriptase-
2wt-transfected cells (Figure 4C). Neither s-HJV nor m-HJV
was cleaved, indicating that the released serine-protease do-
main is inactive on HJV.Cell Metabolism 8, 502–511, December 3, 2008 ª2008 Elsevier Inc. 505
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(A) HeLa cells were transfected with HJV in the presence of the empty vector (mock), matriptase-2wt (MT2wt), MT2R774C, and MT2MASK. Whole cell extracts, con-
centrated media, and PI-PLC supernatants were loaded onto a 10% SDS-PAGE and processed for western blot analysis. Anti-FLAG and anti-HJV were used to
detect MT2 and HJV, respectively. b-ME: beta-mercaptoethanol.
(B) Binding assay was used to measure m-HJV in the presence of increasing concentrations of wild-type and mutants MT2 expressing vectors and was per-
formed essentially as described in Figure 1B. Experiments were made in triplicate and performed three times. Error bars indicate SD. Exact P values refer to
MT2wt versus MT2R774C.
(C) HeLa cells were transfected with MT2wt and MT2MASK, in the presence of HJVwt, HJVW191C and HJVR335Q. Whole cell extracts, concentrated media, and PI-
PLC supernatants were loaded onto a 10% SDS-PAGE and processed for western blot analyses. s-HJV: soluble HJV; m-HJV: membrane associated HJV; CL:
cellular lysates; CM: conditioned medium; PI-PLC: supernatant after PI-PLC cleavage. The equal loading was verified by a-tubulin.HJV Interacts with Matriptase-2
Our results demonstrate that matriptase-2 specifically cleaves
m-HJV, generating the 25–30 kDa soluble fragments. If overex-
pressed, matriptase-2 causes a reduction of all HJV species in-
cluding the 42 kDa soluble form.
To test whether the two proteins interact, HeLa cells were tran-
siently transfected with matriptase-2wt, in the presence of HJV or
an empty vector. Two days after transfection, cell lysates were
immunoprecipitated with the anti-HJV antibody and the immu-
noprecipitates were analyzed by immunoblotting with anti-
FLAG, which recognizes matriptase-2. The anti-HJV immuno-
precipitate showed the presence of matriptase-2 (Figure 5A).
To confirm the specificity of the interaction, matriptase-2 was
immunoprecipitated by the anti-FLAG, and the precipitates ana-
lyzed with anti-HJV. Matriptase-2 forms a complex with HJV.
HJV also specifically coimmunoprecipitates with matriptase-
2MASK (Figure 5B), demonstrating that the matriptase-2 ectodo-
main is involved in HJV interaction.We observed that the amount
of matriptase-2MASK precipitated with HJV was greater than that
of matriptase-2wt, likely because the proteolytic activity of the
overexpressed matriptase-2 cleaved HJV. The matriptase-
2R774C variant also maintains the ability to interact with HJV
(data not shown).
Expression of Mutant Matriptase-2 in Zebrafish
Leads to a Dominant Negative Phenotype
Mutations in matriptase-2 show a recessive phenotype in both
mice and humans. Our binding data, however, show that wild-506 Cell Metabolism 8, 502–511, December 3, 2008 ª2008 Elseviertype and mutant matriptase-2 binds to m-HJV. This observation
suggests that highly expressed mutant matriptase-2 might act
as a dominant negative. To test this possibility, we transfected
fertilized zebrafish eggs with plasmids expressing matriptase-
2wt, matriptase-2R774C, or matriptase-2MASK and examined the
effect of these constructs on hematopoiesis, in comparison
with matriptase-2 morpholino (Figure 6). Increased hepcidin ex-
pression by downregulating ferroportin results in iron-limited
erythropoiesis and defects in hemoglobinization in matriptase-2
mutant mice (Folgueras et al., 2008; Du et al., 2008). Results of
the matriptase-2 morpholino (Figures 6A and 6B) indicate that
this occurs also in zebrafish. Expression of matriptase-2wt had
no effect on hemoglobin production, whereas expression of ma-
triptase-2MASK severely affected hemoglobin production as well
as resulting in smaller fish. Expression of matriptase-2R774C re-
duced hemoglobin production, although to a lesser extent than
matriptase-2MASK (Figures 6C and 6D). This result is consistent
with matriptase-2R774C showing partial activity. As zebrafish
has an endogenous matriptase-2, our results support the hy-
pothesis that the highly expressed mutant protein binds to the
endogenous HJV. Injection of fertilized eggs with iron sup-
pressed the hemoglobinization defect in matriptase-2R774C-
transfected animals, but only partially suppressed the defect
when matriptase-2MASK was transfected. This result may derive
from the fact that the amount of injected iron is limiting and can
only correct the defect with a partially active matriptase or that
a mutant matriptase-2 may have effects beyond modulation of
iron metabolism.Inc.
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(A) HeLa cells were transfectedwith empty vector ormatriptase-2 (MT2) expressing plasmid, and then incubatedwith an exogenous source of soluble HJV.Whole
cell extracts and concentrated media were then analyzed by western blot. A scheme of the experiment is shown bottom left.
(B) HeLa cells were transfected with HJV and increasing concentration of MT2wt expressing vectors. Whole cell extracts, concentrated media, and PI-PLC
derived supernatants were then analyzed by western blot.
(C) HeLa cells were transfected with HJV cDNA expressing vector and incubated with exogenous soluble MT2. Whole cell extracts, concentrated media, and PI-
PLC-derived proteins were analyzed by western blot. A scheme of the experiment is shown bottom right. s-HJV and s-MT2 refer to soluble proteins. m-HJV
indicates membrane-bound HJV; CL: cellular lysates; CM: conditioned medium; PI-PLC: supernatant after PI-PLC cleavage. The equal loading was verified
by a-tubulin.DISCUSSION
Increasing evidence indicates that theexpressionof hepcidin, the
key regulator of enteric iron absorption and macrophage iron re-
lease to plasma, is tightly regulated. In conditions of iron defi-
ciency the expression of hepcidin must be suppressed to in-
crease iron export through ferroportin to plasma transferrin.
Proposed inhibitors of hepcidin are HIF-1a (Peyssonnaux et al.,
2007), which is increased in hypoxia/iron deficiency and s-HJV,
which downregulates hepcidin in vitro (Lin et al., 2005) and
in vivo (Babitt et al., 2007). s-HJV administration in mice causes
ironoverload, identical in theeffect to the lackofm-HJV, strength-
ening the fundamental role of HJV in the hepcidin pathway.
Inactivation of matriptase-2 results in excessive hepcidin pro-
duction in iron deficiency both in mice and humans. We demon-
strated that matriptase-2, cotransfected with HJV in Hep3B
cells, was able to inhibit hepcidin activation in a Hep-Luc assay,
whereas matriptase-2MASK was inactive, confirming the original
observation in HepG2 cells (Du et al., 2008). The human matrip-
tase-2R774C mutant showed decreased inhibitory activity and
only inhibited hepcidin when expressed at high concentrations.
Matriptase-2 was effective only in the presence of HJV and
had no effect in basal conditions or in cells treated with BMP2,Celllikely because of the extremely low endogenous HJV in Hep3B
cells (Lin et al., 2005; Babitt et al., 2006). The hepcidin response
to BMP maintained in cells transfected with matriptase-2 indi-
cates the integrity of the BMP receptors, excluding BMP recep-
tors as potential targets of matriptase-2. Consistent with their
effect on hepcidin expression, matriptase-2 was able to cleave
HJV exposed on cell surface,matriptase-2R774C had reduced ac-
tivity, and matriptase-2MASK had no cleavage activity. The resid-
ual amount of HJV on cell membrane revealed by binding assay
or PI-PLC in cells transfected with matriptase-2wt and mutants
agreed well with the effect of the corresponding mutant on the
hepcidin promoter. Beside the 42 and 33 kDa soluble forms, cells
cotransfected with HJV and matriptase-2 release other smaller
size C-terminal fragments in the culture supernatants. To estab-
lish their origin we analyzedHJVW191C, which is barely present on
plasmamembrane but releases 42 kDa s-HJV in the supernatant
(Silvestri et al., 2007), and the furin cleavage mutant R335Q,
which is present on plasma membrane, but does not release
soluble components (Silvestri et al., 2008). After matriptase-2
cotransfection, only HJVR335Q releases the same 25–30 kDa
fragments as HJVwt, strengthening themembrane origin of these
fragments. Whether these peptides have any physiological role
in iron deficiency remains to be investigated.Metabolism 8, 502–511, December 3, 2008 ª2008 Elsevier Inc. 507
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fected cells in the presence of matriptase-2. This is compatible
with the strong decrease of HJV in whole-cell extracts due to
the proteolytic activity of the overexpressed matriptase-2 and
strongly supports the assumption that s-HJV is secreted by
an intracellular mechanism (Silvestri et al., 2008). Testing the
ability of matriptase-2-transfected cells to cleave exogenous
Figure 5. Matriptase-2 Interacts with HJV
(A and B) HeLa cells were cotransfected with matriptase-2wt (MT2wt) (A) and
MT2MASK (B) in the presence of HJV or an empty vector. Precleared whole
cell extracts were immunoprecipitated with anti-HJV and revealed with the
anti-FLAG antibody, which recognizes MT2 (A and B) or immunoprecipitated
with anti-FLAG and revealed with anti-HJV (A). To control for transfection,
whole cell extracts were loaded and revealed with anti-HJV and anti-FLAG
antibodies.508 Cell Metabolism 8, 502–511, December 3, 2008 ª2008 Elseviers-HJV we formally exclude a cleavage activity of matriptase-2
on s-HJV, suggesting that matriptase-2 is active only if coex-
pressed with HJV. As a further proof that matriptase-2 targets
m-HJV, at low concentration it does not cleave the other HJV
species.
Although it has been shown that in vitro matriptase-2 cleaves
extracellular matrix proteins (Velasco et al., 2002), the full-length
protease specifically targets m-HJV. The specificity is ac-
counted for by the physical interaction of the two proteins. The
interaction occurs at the matriptase-2 ectodomain and does
not require the serine protease domain, as shown by the positive
results of coimmunoprecipitation of HJV with matriptase-2MASK.
In agreement, matriptase-2wt does not cleave exogenous s-HJV
and the released serine protease domains appear inactive on
HJV.
The reduced hemoglobinization of zebrafish matriptase-2
morpholino confirms a conserved function for this serine prote-
ase and emphasizes that the iron regulatory mechanisms are
highly evolutionarily conserved. Decreased hemoglobinization
observed in zebrafish overexpressingmutantsmatriptase-2 indi-
cates that the interaction betweenmatriptase-2 andHJV—which
we have demonstrated in vitro—occurs in vivo. Despite having
a normal endogenous matriptase-2, matriptase-2MASK-injected
fishes are anemic, supporting the hypothesis that the highly ex-
pressed humanmutant protein binds to the endogenous Hjv and
behaves like a dominant negative mutant.
The ability of matriptase-2 to cleave a GPI-linked protein ap-
pears analogous to that of its homolog matriptase-1, an ubiqui-
tous transmembrane serine protease of the same TTSP family,
which activates a GPI-serine protease (Leyvraz et al., 2005;Figure 6. Expression of Mutants Matriptase-2 in Zebrafish Affects Hemoglobinization of Erythrocytes
(A) Zebrafish embryos were injected with control (zcontrolMO) and matriptase-2 morpholino (zmt2MO). Fourty-eight hours post injection, embryos were stained
with o-dianisidine to detect hemoglobinized cells.
(B) Embryos as in (A) were homogenized, and RNAwas extracted as described in Experimental Procedures. RT-PCR was performed using oligonucleotides spe-
cific for matriptase-2 (zmt2) and for the elongation factor 1a (zef1a). Four-hundred fifty embryos were injected, and the survival rate was 85%.
(C) Zebrafish embryos were injected with matriptase-2wt (MT2wt), MT2R774C, and MT2MASK expressing vectors, in the presence (+Fe) or not (Fe) of iron dextran.
At 48 hr after fertilization embryos were stained with o-dianisidine to detect hemoglobinized cells. Representative pictures of the injected fishes (200 for each
construct, made in triplicate) are shown.
(D) MT2 levels were assayed by western blot analysis.Inc.
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BMP-HJV-Hepcidin Pathway
(A) Schematic representation of amodel of matrip-
tase-2 activity in iron deficiency. On the left, the
serine protease cleaves m-HJV releasing soluble
fragments (here simplified by the black boxes).
The cleavage sites of matriptase-2 are unknown.
The question mark indicates uncertainty on frag-
ments function. The resulting hepcidin inhibition
is shown. The complementary effect of s-HJV,
produced by furin cleavage, to sequester BMP is
shown on the right.
(B) Lack of hepcidin inhibition in the presence of
matriptase-2 mutations. m-HJV acts as BMP cor-
eceptor and permits hepcidin production in iron
deficiency; the effect of s-HJV cannot downregu-
late hepcidin in the presence of m-HJV.Netzel-Arnett et al., 2006). Mutations of matriptase-1 in a mouse
model cause ichthyosis with hypotrichosis syndrome, a disorder
of the epidermal and oral barrier function (Basel-Vanagaite et al.,
2007).
It has been proposed that activation of signaling through ma-
triptase-2 depends upon the proteolytic cleavage event and
occurs through the protein cytoplasmic tail (Du et al., 2008).
Although nomutants have yet been found at this level, we cannot
exclude that the activated cytoplasmic tail signals the iron status
to a novel pathway involved in the response to iron deficiency
(Du et al., 2008). However, our data emphasize that the inhibitory
effect on hepcidin requires the m-HJV cleavage. Published
studies suggest that the proteolytic activity of matriptase-2 is
essential for its function (Du et al., 2008; Finberg et al., 2008),
and the studies presented here demonstrate that HJV is the sub-
strate for that activity. In analogywithmatriptase-1, the cytoplas-
mic and transmembrane domains of matriptase-2 might contrib-
ute to the targeting of the protein to a particular plasma
membrane side in polarized hepatocytes. Interestingly, rat ma-
triptase-1 expression on intestinal Caco-2 cells results in protein
localization almost exclusively on the basolateral side (Satomi
et al., 2001).
Matriptase-2 shows tissue-restricted, strong liver expression.
It is thus quite reasonable that its proteolytic activity responds to
iron deficiency, in order to downregulate the hepcidin-activating
pathway, based on m-HJV as BMP coreceptor. However, we
suggest that the pathway may still be modulated by s-HJV,
which inhibits BMP-dependent hepcidin activation (Figure 7).
Hepatocytes from Hjv/ mice are still able to transcribe hepci-
din (although to a lesser extent than wild-type) in response to
BMP (Babitt et al., 2006), and matriptase-2 is unable to block
BMP2-dependent hepcidin activation in our model (Figure 2A).
Soluble HJV, originated from hepatocytes or skeletal muscles,
might block the residual BMP-mediated hepcidin activation to
fully switch off the pathway in iron deficiency. In this way, the in-
hibition of hepcidin will be stronger than that obtained by the ef-
fect of matriptase-2 alone. In agreement with this interpretation,
s-HJV appears not to substitute for the lack of matriptase-2. In
conclusion, molecular mechanisms of hepcidin downregulation
by s-HJV and by matriptase-2 converge on the BMP-HJV path-Cellway. Whether the matriptase-2 activity may be modulated by
other hemochromatosis proteins is an issue for further research.
EXPERIMENTAL PROCEDURES
Matriptase-2- and HJV-Expressing Vectors
The full-length human matriptase-2 cDNA (NM_153609; C-terminal FLAG-
tagged) in pcDNA3.1 was kindly provided by Professor Carlos Lopez-Otin
(Departamento de Bioquimica y Biologia Molecular-IUOPA, Universidad de
Oviedo, Spain). The matriptase-2R774C variant (Finberg et al., 2008) was ob-
tained by mutagenesis of the wild-type cDNA by using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA), according to the manufac-
turer’s protocol. Matriptase-2MASK, lacking the serine protease domain
(Du et al., 2008), was obtained by cloning the cDNA encoding the truncated
protein into the EcoRI and XbaI sites of pcDNA3.1(+) (see the Supplemental
Data for oligonucleotide sequences).
Expressing vectors encoding HJVwt, HJVW191C HJVR335Q were obtained as
described (Silvestri et al., 2007; Silvestri et al., 2008).
Cell Culture and Reagents
Cell-culture media and reagents were from Invitrogen and Sigma-Aldrich (St.
Louis, MO).
HeLa cells, which do not express endogenousHJV, andHep3B cells were cul-
tured respectively inDulbecco’smodifiedEagle’smedium (DMEM)and inEarle’s
minimal essential medium (EMEM), supplemented with 2 mM L-glutamine,
200 U/ml penicillin, 200 mg/ml streptomycin, 1 mM sodium pyruvate, and 10%
heat-inactivated fetal bovine serum (FBS) at 37C in 95% humidifier air and 5%
CO2. The rabbit polyclonal antisera directed against HJV was obtained as de-
scribed (Silvestri et al., 2008). Briefly, the cDNA fragment encoding from amino
acids 226–402 of human HJV was cloned into a pGEX (Amersham Biosciences
EuropeGmbH,Freiburg,Germany) vector in fusionwithGST. Theproteinwasex-
pressed inEscherichia coli, purifiedby affinity chromatography, and used to elicit
antibodies in rabbit.Anti-tubulin, anti-FLAG,andanti-cMYCantibodieswere from
Santa Cruz Biotechnology (Santa Cruz, CA) and Sigma-Aldrich, respectively.
Luciferase Assay
A pGL2-basic reporter vector (Promega, Madison, WI, USA) containing a
2.9 Kb fragment of the human hepcidin promoter (Hep-Luc) (Pagani et al.,
2008) was used to monitor the hepcidin promoter activation by luciferase
assay.
Hep3B cells, seeded at 70%–80% of confluency, were transiently trans-
fected with 0.25 mg hepcidin promoter luciferase reporter construct in combi-
nation with pRL-TK Renilla luciferase vector (Promega) to control transfection
efficiency, and with 0.1 mg/ml of expressing vectors encoding wild-type or mu-
tant HJV. Eighteen hours after transfection the medium was changed, cellsMetabolism 8, 502–511, December 3, 2008 ª2008 Elsevier Inc. 509
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lysed. When indicated, 50 ng/ml of BMP2 was added to the cell culture. Lucif-
erase activity was determined according to manufacture’s instructions (Dual
Luciferase Reporter Assay, Promega). Relative luciferase activity was calcu-
lated as the ratio of firefly (reporter) to Renilla luciferase activity and expressed
as a multiple of the activity of cells transfected with the reporter alone. Exper-
iments were performed in triplicate.
Western Blot Analysis
HeLa cells, seeded in 100-mm-diameter dishes up to 70%–80% of conflu-
ency, were transiently transfected with 20 mg of plasmid DNA and 50 ml of
the liposomal transfection reagent Lipofectamine 2000 (Invitrogen) in 3 ml of
OptiMem (Invitrogen) according to the manufacturer’s instructions. After
18 hr the medium was replaced with 4 ml of OptiMem and 24 hr later media
were collected and concentrated using 5 kDamolecular weight (MW) cutoff ul-
trafiltration (Amicon Ultra; Millipore, Billerica, MA), and cells were lysed in RIPA
buffer. Proteins were quantified by using the Bio-Rad Protein Assay (Bio-Rad,
Hercules, CA); equal amount of total proteins (50 mg) were subjected to 10%
SDS-PAGE and then transferred to Hybond C membrane (Amersham Biosci-
ences Europe GmbH, Freiburg, Germany) by standard western blotting tech-
nique. Blots were blocked with 2% ECL Advance Blocking Agent (Amersham
Biosciences) in TBS (0.5 M Tris-Hcl [pH 7.4] and 0.15 MNaCl) containing 0.1%
Tween-20 (TBST), incubated 2 hr with rabbit anti-HJV (1:1000), rabbit anti-
FLAG (1:1000), or mouse anti-tubulin (1:500). After washing with TBST, blots
were incubated 1 hr with relevant HRP-conjugated secondary antisera and de-
veloped using a chemiluminescence detection kit (ECL, Amersham Biosci-
ences).
Immunoprecipitation
Immunoprecipitation was performed as follows. Transfected cells were lysed
in NET/Triton buffer (150 mM NaCl, 5 mM EDTA, and 10 mM Tris [pH 7.4]
with 1% Triton X-100). Total lysates were cleared with 20 ml of Protein A/G
Plus Agarose (Santa Cruz, CA) and 2 ml of irrelevant antibodies (sera from rab-
bit or mouse) and 500 mg of precleared lysateswere incubated with anti-HJV or
anti-FLAG at 4C. After 1 hr, 20 ml of Protein A/G Plus Agarose were added and
incubated at 4C for 12 hr, followed by three washings with NET/Triton buffer.
Samples were then eluted with 25 ml of Laemmli sample buffer two times and
subjected to SDS-PAGE on 10% acrylamide gel. Immunodetection was per-
formed as described above, except that rabbit TrueBlot (eBioscience,
1:1000 dilution), which does not recognize denatured IgG was used as the
secondary antibody.
Electron Microscopy and Morphometric Analysis
HeLa cells were transiently transfected with Lipofectamine 2000 using
pcDNA3.1-matriptase-2 (matriptase-2wt), pcDNA3.1-matriptase-2MASK (ma-
triptase-2MASK) and pcDNA3.1-matriptase-2R774C (matriptase-2R774C) con-
structs. After 18 hr, cells were fixed, labeled with a polyclonal rabbit anti-
FLAG using the gold-enhance protocol, embedded in Epon-812, and cut as
described. Immunoelectron microscopy (EM) images were acquired from
thin sections under a Philips Tecnai-12 electron microscope (Philips, Eind-
hoven, the Netherlands) using an ULTRA VIEW CCD digital camera (Philips).
Thin sections were also used to quantify gold particles residing within different
compartments of the secretory pathway.
Analysis of Soluble HJV
HeLa cells were transiently transfected for 18 hr, as described in ‘‘Western Blot
Analysis,’’ with HJVwt-, HJVW191C-, or HJVR335Q-expressing vectors in the
presence of matriptase-2wt cDNA,matriptase-2MASK, or matriptase 2R774C var-
iants. Cells were then incubated with serum-free media, which were collected
after 24 hr, concentrated using Amicon Ultra, and analyzed by SDS-PAGE.
When indicated, HJV- or matriptase-2-transfected cells were incubated for
24 hr with matriptase-2- or HJV-conditioned cell-culture media (see Supple-
mental Experimental Procedures for details). Soluble, membrane and whole
cellular proteins were then analyzed by SDS-PAGE.
Cell-Surface Protein Quantification by Binding Assay
Quantification of cell-surface expression of HJV and/or matriptase-2-express-
ing vectors were performed as described, with minor modifications. In brief,510 Cell Metabolism 8, 502–511, December 3, 2008 ª2008 Elsevier104 HeLa cells were seeded in 48-well plates and transfected with 0.4 mg of
plasmid DNA complexed with 1 ml of Lipofectamine 2000, according to the
manufacturer’s instructions. After 12 hr, the medium was replaced and,
24 hr later, cells were fixed with 4% paraformaldehyde for 45min at room tem-
perature. Cells were washed with PBS, blocked with 5% nonfat milk in PBS,
and incubated with rabbit anti-HJV (1:1000) or rabbit anti-FLAG (1:1000) and
thenwith the relative secondary HRP antibody at 37C. For total HJV ormatrip-
tase-2 expression, cells were permeabilized with 0.1% Triton X-100 in PBS,
prior to blocking and incubation with anti-HJV or anti-FLAG. Peroxidase activ-
ity was measured with an HSR substrate (o-phenylenediamine dihydrochlor-
ide), according to the manufacturer’s instructions. The amount of m-HJV or
m-matriptase-2 was calculated as the ratio between the absorbance of unper-
meabilized and permeabilized cells. Background absorbance was subtracted
for each sample. The Student’s t test was used for statistical calculation.
PI-PLC Cleavage of Membrane HJV
A total of 106 HeLa cells, transiently transfected with HJV- and matriptase-2-
expressing constructs or the empty vector were incubated in DMEM plus
0.3 U/ml phosphatidylinositol-specific phospholipase C (PI-PLC) at 37C in
a 5% CO2 incubator. After 2 hr, the supernatants were collected. Proteins
were precipitated with cold acetone and resuspended in Laemmli sample
buffer, in the presence of 4% v/v b-mercaptoethanol (b-ME) when indicated.
Samples were then boiled for 10 min and loaded on a 10% SDS-PAGE.
Zebrafish Embryo Cultures and Injection
Danio rerio (Zebrafish) were maintained as described (De Domenico et al.,
2007). Matriptase-2-expressing vectors were purified using EndoFree Purifi-
cation Kit (QIAGEN, Chatsworth, CA). Embryos at stage 1 cell were injected
with 50 pg DNA and, when indicated, 100 mg/ml of iron dextran solution
(PIGDEX, American Cyanamid Co.; Princeton, NJ). At 48 hr after fertilization
embryos were stained with o-dianisidine for erythrocytes, and proteins were
extracted as described previously (De Domenico et al., 2007). Western blot
analyses were performed using mouse anti-FLAG (Sigma, 1:5000) followed
by peroxidase-conjugated goat anti-mouse IgG (1:10,000, Jackson Immuno-
Research Labs; West Baltimore Pike West Grove, PA).
Matriptase-2 morpholino antisense oligonucleotide was synthezised (50-
GAACACCGCCATCTGAAAACAAATA-30; intron 2:exon 3 junction) (Gene
Tools LLC; Corvaliss, OR). A morpholino provided by GeneTools was used
as a negative control. One-cell wild-type zebrafish embryos were injected
withmorpholino into the yolk. For each injection, 450 embryoswere used. After
48 hr postinjection embryos were stained as above and total RNA was ex-
tracted using RNeasy (QIAGEN; Valencia, CA). Zebrafish matriptase-2 (zmt2)
RT-PCR was performed on RNA from dechorionated zebrafish embryos using
the following primers:
zmt2-sense: 50-CTCCTGAGAGGCTCCAACAC-30;
zmt2-antisense: 50-CTGCTCTCCAACTCCACCTC-30.
Zebrafish elongation factor 1a (zef1a) was used as a loading control:
zef1a-sense: 50-GATGCACCACGAGTCTCTGA-30;
zef1a-antisense: 50-TGATGACCTGAGCGTTGAAG-30.
SUPPLEMENTAL DATA
Supplemental Data include two figures and Supplemental Experimental Pro-
cedures and can be found online at http://www.cell.com/cellmetabolism/
supplemental/S1550-4131(08)00319-7.
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